The MGH Cancer Center and the Wellcome Trust Sanger Institute of the United Kingdom have begun a new alliance in cancer genome research.
MGH Hotline 2.6.09 The MGH community is invited to attend the annual Celebration of Science Feb. 11 and the Scientific Advisory Committee (SAC) meeting Feb. 12.
MGH Hotline 5.15.09 Exactly 100 flowers were planted in the Howard Ufelder, MD, Healing Garden April 28 to recognize the newly announced members of the one hundred – 100 groups and individuals who are making a difference in cancer care.
MGH Hotline 05.29.09 The MGH Cancer Center has been awarded a $15 million research grant from the proceeds raised by the landmark Sept. 5, 2008 Stand Up to Cancer (SU2C) telethon.
MGH Hotline 10.16.09 Seven MGH-affiliated physicians and researchers join prestigious Institute of Medicine seven MGH-affiliated physicians and researchers were among the 65 new members and five foreign associates recently elected to the prestigious Institute of Medicine (IOM), a recognized leader for independent, scientifically informed analysis and recommendations on health issues.
MGH Hotline 06.25.10 MORE THAN 650 guests attended the MGH Cancer Center’s annual fundraiser, the one hundred, held June 2 at the Westin Boston Waterfront.
ALL MGHERS are invited to attend the 2011 meeting of the MGH Scientific Advisory Committee (SAC), which will commemorate the hospital’s bicentennial with a look back at significant research accomplishments of MGH investigators and examine challenges facing today’s research community.
The 64th meeting of the MGH Scientific Advisory Committee (SAC) on April 14 celebrated key accomplishments of MGH investigators, past and present, and examined strategies for meeting the challenges currently facing the academic biomedical research community.
The MGH Cancer Center presented its annual MGH Award in Cancer Research on April 8 to Michael R. Stratton, MD, PhD, director of the Wellcome Trust Sanger Institute.
MGH Hotline 5.27.11 In General
MGH Hotline 6.10.11 Selected from among 115 applications from across the MGH research community, the inaugural MGH Research Scholars recently were announced at the annual meeting of the MGH Research Advisory Council (RAC).
The Mass General Cancer Center hosted the seventh annual the one hundred gala on June 10.
Daniel A. Haber, MD, PhD, director of the MGH Cancer Center, and Kate Robbins, a 10-year survivor of advanced stage lung cancer, were among the many models who walked the runway at the Friends of the Mass General Cancer Center Fall Benefit: Couture for Cancer Care at the Revere Hotel in Boston.
A team of researchers led by Daniel Haber, MD, PhD, director of the MGH Cancer Center, recently announced that they have revealed a unique molecular mechanism that might control the growth of cancer cells.
The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at the MGH Cancer Center and the Wellcome Trust Sanger Institute, describe the responses of 350 cancer samples to 18 anticancer therapeutics.
MGH Cancer Center researchers have discovered a previously unknown feature of common tumor cells – massive overexpression of satellite repeats, which are DNA sequences that do not code for proteins. The findings may improve understanding of tumor development and provide a new cancer biomarker.
Researchers from the MGH Cancer Center have identified a new potential strategy for treating colon tumors driven by mutations in the KRAS gene, which usually resist both conventional and targeted treatments.
In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalized approach to cancer treatments.
Detailed analysis of genes expressed in circulating tumor cells – cells that break off from solid tumors and travel through the bloodstream – has identified a potential treatment target in metastatic pancreatic cancer.
A new system for isolating rare circulating tumor cells – living solid tumor cells found at low levels in the bloodstream – shows significant improvement over previously developed devices and does not require prior identification of tumor-specific target molecules.